I don't recall seeing talk of this on the board but I'll

New Post Public Reply Private Reply Replies (3) Message Board
Respert24
862
I don't recall seeing talk of this on the board but I'll admit that I haven't paid as close attention as I would if something interesting was going on and/or the share price wasn't below the turd line (investing term). Perhaps this is why they're apparently making kissy faces with Pestell? Probably can't file patents if the person half responsible isn't "on board".

https://uspto.report/patent/app/20220162327

"U.S. patent application number 17/598650 was filed with the patent office on 2022-05-26 for anti-ccr5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by dna damaging chemotherapy. The applicant listed for this patent is CytoDyn Inc.. Invention is credited to Scott KELLY, Richard G. Pestell.

ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY

Abstract
The present disclosure relates to the use of DNA damaging agents and leronlimab (PRO 140), or other anti-CCR5 agents, to treat or prevent cancer metastases and enhance the cell killing ability of the DNA damaging agents by selectively targeting the CCR5 receptor. The present disclosure relates to the use of DNA damaging agents and leronlimab (PRO 140), or other anti-CCR5 agents, to treat or prevent cancer metastases and reduce circulating tumor cells (CTC) or putative metastatic tumor cells in the peripheral blood following treatment, reduce CCR5 expression on cancer-associated cells after following treatment, decrease volume in tumor size following treatment. The present disclosure may be used to treat or prevent subjects with cancer and, particularly, subjects with metastatic CCR5+ cancer.

Inventors: KELLY; Scott; (Vancouver, WA) ; Pestell; Richard G.; (Vancouver, WA)

Family ID: 1000006184697
Appl. No.: 17/598650
Filed: April 1, 2020
PCT Filed: April 1, 2020
PCT NO: PCT/US2020/026253
371 Date: September 27, 2021"

There's more at the link, I just posted some of the quick and dirty stuff. I feel like this is an ongoing patent application rather than a brand new one, at least based on the fact that you see some dates listed as far back as 2019 in the link. But clearly it states that this has been filed by SK and RP just a few weeks back, so I'm not sure what exactly is new or not. Hoping someone here recalls enough of old patent attempts or has a great knowledge of these postings to figure out if there's any new meat on this goddamn bone, as Warren Buffet is famous for saying.

And for those playing at home, I'm still not planning on using the 144k that improperly deposited into my account, but don't think I didn't daydream about it almost all day yesterday.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 3

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 10

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

NCLA Seeks Supreme Court's Support for Presidential Authority

Updated Category News Views 160

NCLA Seeks Supreme Court's Support for Presidential Authority Washington, DC, the New Civil Liberties Alliance (NCLA) has taken significant legal action recently, filing an amicus curiae brief in a pivotal Supreme Court case concerning presidential power. The organization argues for the President's authority to remove a member of the Federal Reserve Board, specifically...

Continue Reading
ONAR CEO Claude Zdanow to Discuss AI Innovations at 2025 Event

Updated Category News Views 226

ONAR CEO Claude Zdanow to Present at GenAi Week SV 2025 ONAR Holding Corporation (OTCQB: ONAR), a prominent marketing-technology firm, has announced an exciting opportunity for its CEO, Claude Zdanow, to present at GenAi Week SV 2025. This key industry event promises to gather innovators and leaders in the field of generative AI, uniting enthusiasts eager to explore...

Continue Reading
Foremost Clean Energy Clarifies Spin-Out and Trading Halt

Updated Category News Views 148

Understanding the Recent Updates from Foremost Clean Energy Foremost Clean Energy Ltd. (NASDAQ: FMST), a burgeoning player in North America's uranium and lithium exploration sector, aims to clarify important developments regarding its operations, particularly the anticipated spin-out of its gold and silver properties into a new entity, Rio Grande Resources Ltd. Clarity on...

Continue Reading
Nexar and NVIDIA Pioneer Autonomous Vehicle Solutions Together

Updated Category News Views 310

Nexar and NVIDIA Join Forces for Automotive Innovation The collaboration between Nexar and NVIDIA is set to revolutionize the field of autonomous vehicles. By leveraging Nexar's vast real-world vision data alongside NVIDIA's powerful computing capabilities, this partnership aims to redefine safety and innovation in mobility solutions. Transforming Data into Actionable...

Continue Reading
National Grid Renewables Launches 117 MW Solar Project

Updated Category News Views 175

National Grid Renewables Breaks Ground on Sycamore Creek Solar Project The Sycamore Creek Solar Project is an exciting new initiative that demonstrates National Grid Renewables' commitment to sustainable energy. Located within the PJM market, this project has a capacity of 117 megawatts (MW) and is set to make significant contributions to the local economy. Commitment to...

Continue Reading